
|Articles|March 1, 2004
CMS expands coverage for OPT with verteporfin
Washington, DC-The Centers for Medicare and Medicaid Services (CMS) once again plans to expand its coverage for ocular photodynamic therapy (OPT) with verteporfin (Visudyne, Novartis Ophthalmics).
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Retina Society 2026: MCO-010 optogenetic therapy maintains visual acuity gains through 4 years in advanced RP
2
Manju Subramanian, MD: anti-VEGF linked to kidney function decline
3
Retina Society 2026: Medium-dose OCU410 gene therapy cuts geographic atrophy progression by up to 32% in phase 2 trial
4
Remigromig noninferior to ranibizumab in phase 2b/3 BRUNELLO DME trial
5












